Table 1—

Patient characteristics at randomization into the study

VariableConventional glucose control policyIntensive glucose control policy
All
Insulin aloneChlorpropamide (± insulin)Glipizide (± insulin)
n 242 245 169 170 826 
Sex (% male) 59 60 56 63 59 
Ethnic group (%)      
    White Caucasian 77 80 79 77 79 
    Afro-Caribbean 
    Indian Asian 18 16 16 18 16 
Age (years) 52 ± 9 52 ± 9 52 ± 10 52 ± 10 52 ± 9 
Fasting plasma glucose (mg/dl) 149 (131–184) 151 (130–185) 149 (130–182) 149 (128–176) 149 (130–182) 
HbA1c (%) 7.0 (6.2–8.1) 6.9 (6.1–8.0) 6.9 (6.0–8.1) 6.9 (6.0–7.7) 6.9 (6.1–8.0) 
Weight (lb) 180 ± 40 180 ± 40 176 ± 37 178 ± 37 178 ± 37 
BMI (kg/m228.8 ± 5.9 29.3 ± 6.4 28.4 ± 4.9 28.5 ± 5.5 28.8 ± 5.8 
Systolic blood pressure (mmHg) 132 ± 19 134 ± 21 133 ± 20 131 ± 19 132 ± 20 
Diastolic blood pressure (mmHg) 80 ± 10 82 ± 11 81 ± 10 80 ± 10 81 ± 10 
VariableConventional glucose control policyIntensive glucose control policy
All
Insulin aloneChlorpropamide (± insulin)Glipizide (± insulin)
n 242 245 169 170 826 
Sex (% male) 59 60 56 63 59 
Ethnic group (%)      
    White Caucasian 77 80 79 77 79 
    Afro-Caribbean 
    Indian Asian 18 16 16 18 16 
Age (years) 52 ± 9 52 ± 9 52 ± 10 52 ± 10 52 ± 9 
Fasting plasma glucose (mg/dl) 149 (131–184) 151 (130–185) 149 (130–182) 149 (128–176) 149 (130–182) 
HbA1c (%) 7.0 (6.2–8.1) 6.9 (6.1–8.0) 6.9 (6.0–8.1) 6.9 (6.0–7.7) 6.9 (6.1–8.0) 
Weight (lb) 180 ± 40 180 ± 40 176 ± 37 178 ± 37 178 ± 37 
BMI (kg/m228.8 ± 5.9 29.3 ± 6.4 28.4 ± 4.9 28.5 ± 5.5 28.8 ± 5.8 
Systolic blood pressure (mmHg) 132 ± 19 134 ± 21 133 ± 20 131 ± 19 132 ± 20 
Diastolic blood pressure (mmHg) 80 ± 10 82 ± 11 81 ± 10 80 ± 10 81 ± 10 

Data are means ± SD or median (IQR).

Close Modal

or Create an Account

Close Modal
Close Modal